Ustekinumab Intravenous (Stelara® , Otulfi™, Pyzchiva® , Selarsdi™, Steqeyma™, Wezlana™, Yesintek™, ustekinumab-ttwe)

Covers a single weight‑based intravenous induction dose of ustekinumab for adults (≥18) with moderately‑to‑severely active Crohn’s disease or ulcerative colitis and excludes pediatric patients and maintenance dosing (approval limited to 30 days); mesalamine does not count as prior systemic therapy. Approval requires gastroenterologist prescribing/consultation, documentation of diagnosis and patient weight, and meeting disease‑specific criteria (Crohn’s: ileocolonic resection, enterocutaneous/rectovaginal fistulas, trial/failure of one other systemic agent, trial/current systemic corticosteroid, or corticosteroid contraindication; UC: trial/failure of one other systemic agent or pouchitis with trial of specified local therapies) with weight‑based IV dosing of 260 mg (≤55 kg), 390 mg (>55–85 kg), or 520 mg (>85 kg).

"For ulcerative colitis: Ustekinumab intravenous will be used as induction therapy"